Shots:

• The company reported the commercial availability of Trulance for the treatment of IBS-C in Canada & provides a solution to meet the treatment gap for patients with the same indications
• The results from the 2 clinical trials of Trulance showed a significant patient self-evaluated reduction in IBS disease severity & reduction in IBS symptoms over PBO in clinical studies, 30.2% & 21.5% of patients were overall responders & showed a reduction in abdominal pain & improvement in complete spontaneous bowel movements
• Additionally, the incidence of SAEs in patients treated with Trulance was low (0.8%) and similar to PBO while 70% of surveyed IBS-C patients reported the complete relieved in its symptoms

Ref: Newswire.Ca | Image: Rmoto Day